New Advances in Mesenchymal Stromal Cells as Therapeutic Tools, 2nd Edition
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 1230
Special Issue Editor
Interests: immunology; hematology; cell therapy; immunotherapy; transplantation immunology; biopharmaceuticals; bioprocessing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, the need for alternative treatments for various diseases has prompted scientists to focus their attention on cell-based therapies and regenerative medicine. Mesenchymal stromal cells (MSCs) may be isolated from various anatomical sites, including bone marrow, adipose tissue, and the umbilical cord. These cells exhibit potent paracrine properties based on the release of different mediators, including regulatory factors, chemokines, cytokines, growth factors, and nucleic acids, that can be secreted or packaged into extracellular vesicles, and are also implicated in the therapeutic effects of MSCs. The process underlying these effects likely involves the migration and homing of MSCs toward inflamed and injured tissue. During tissue healing, MSCs modulate immune responses and support tissue repair and regeneration. Advances in separation, culture, expansion, and biobanking techniques for MSCs have enabled their large-scale clinical application. This progress has been accompanied by the rapid clinical utilization of MSCs in regenerative and immunomodulatory approaches to treat or prevent diseases.
The purpose of this Special Issue is to bring together contributions from specialists in cellular biology, stem cells, immunology, and bioengineering on the latest advances in the understanding of the mechanisms of action underlying the therapeutic effect of MSCs, in clinical applications of MSCs for the treatment of inflammatory and degenerative diseases/conditions, in developing bioengineering/priming solutions to enhance MSC effectiveness, and in establishing bioprocessing platforms for large-scale MSC production for clinical applications.
We welcome the submission of original research and review articles that cover, but are not limited to, the following topics:
- Cellular and molecular mechanisms underlying the therapeutic effects of MSCs;
- Interactions between MSCs and other cell types in vitro and in vivo;
- Bioengineering/priming solutions to boost the functions of MSCs;
- Bioengineering strategies for improving the administration of MSCs;
- Therapeutic applications of MSCs for inflammatory and degenerative diseases;
- Establishment of bioprocessing platforms for MSC production in a large scale for clinical applications;
- Cellular and molecular changes induced in MSCs during the bioprocess that may compromise their therapeutic potential;
- MSC-derived products (e.g., soluble factors and extracellular vesicles) as mediators of immunomodulation and tissue repair.
Dr. Kelen Cristina Ribeiro Malmegrim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesenchymal stromal cells
- cell therapy
- immunomodulation
- regeneration
- regenerative medicine
- bioprocessing
- bioengineering
- inflammatory diseases
- degenerative diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
